

*Market Scope*®

# 2024 Glaucoma Pharmaceuticals Market Report

Global Analysis for 2023 to 2029

**\$4.2B**

2024 MARKET  
FORECAST

**252**

COMPREHENSIVE  
PAGES

**26**

COMPETITOR  
PROFILES

**8**

GEOGRAPHIC AND  
ECONOMIC BREAKOUTS

# What's New

AUTHOR  
Peter Downs

PUBLISHED  
May 2024

The “2024 Glaucoma Pharmaceuticals Market Report” features new regional sales forecasts that take into account appreciation of the dollar against other major currencies and an updated analysis of the prevalence and diagnosis of glaucoma that reflects COVID-19 mortality. The report now includes market share analysis of generics and branded drugs by drug class in the United States and Japan and prescription stratification by first-line and adjunctive use in the United States and Western European countries.

This new report also provides an updated analysis of the glaucoma pharma product pipeline, a summary of ongoing clinical trials, a review of Glaukos’ recently approved iDose TR sustained drug delivery device, and survey data on US ophthalmologists’ plans for sustained drug delivery.


## Market Scope

# 2024 Glaucoma Pharmaceuticals Market Report


The “2024 Glaucoma Pharmaceuticals Market Report” analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2029 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 26 glaucoma pharmaceutical companies are profiled, discussing their products, strategic market position, background, and outlook. Coverage includes:

- Types of glaucoma and risk factors.
- Diagnosis and treatment of the disease.
- A global view of glaucoma care providers, including ophthalmologists and optometrists.
- Current estimates and five-year forecasts for disease prevalence worldwide.
- Glaucoma medications in the marketplace and their mechanisms of action.
- Discussion of generic versus branded drugs and their market impact.
- The development pipeline for glaucoma pharmaceuticals.
- Profiles of companies making and marketing glaucoma medications.

### Glaucoma Pharmaceuticals Revenue Growth by Region



### Glaucoma Pharmaceuticals Revenue by Market Competitor



This report provides analysis of current markets for glaucoma medications and forecasts market performance over the next five years. The global market is analyzed based on Market Scope's eight regional/economic categories (the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World), and also uses these categories in global forecasts for disease prevalence. In addition, the report explores data and information on the disease process, glaucoma populations, glaucoma care, and a range of additional topics intended to provide depth and context to the reader's understanding of this ophthalmic segment.

## How to Order

Order your "2024 Glaucoma Pharmaceuticals Market Report" now at [www.market-scope.com](http://www.market-scope.com) or contact us directly via email or phone.



### ENTERPRISE LICENSE

2024 Glaucoma Pharmaceuticals  
Market Report

**\$11,850**

*(Price includes a printable PDF and supplemental Excel file with all the tables and figures in the report)*



### SINGLE-USER LICENSE

2024 Glaucoma Pharmaceuticals  
Market Report

**\$8,400**



Printed Copy

**\$250**



### ONE-YEAR SUBSCRIPTION

Ophthalmic Market  
Perspectives Newsletter

**\$1,650**



Monthly Paper Copies

**\$100**

314.835.0600 | [info@market-scope.com](mailto:info@market-scope.com)

## Our Process

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

- Our proprietary global disease population and demographic models
- Analysis of company-published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in worldwide ophthalmic meetings
- Interviews and relationships with company executives and practicing physicians

